Merit Medical Shares Await Key Catalysts for Momentum Shift

Shares of Merit Medical Systems are trading quietly around $93.24 as investors monitor two significant near-term developments. Market attention remains fixed on the company’s upcoming third-quarter results, expected around October 29, and the anticipated December decision regarding transitional pass-through reimbursement approval for the WRAPSODY product.

Market Analysts Maintain Positive Outlook

Financial experts covering Merit Medical maintain an optimistic stance, with nine analysts collectively rating the stock as a “Moderate Buy.” Their average price target of $107.00 suggests potential upside of approximately 14.3% from current trading levels. This bullish perspective reflects confidence in the company’s long-term growth trajectory and positive revenue and earnings projections.

The company’s recent performance supports this optimism. Second-quarter results demonstrated strong operational execution, with GAAP revenue climbing 13.2% to $382.5 million. Non-GAAP earnings per share reached $1.01, surpassing expectations by 18.8%. Based on this robust performance, management raised its full-year guidance for adjusted EPS to a range between $3.52 and $3.72.

WRAPSODY Reimbursement Decision Looms Large

The most significant potential catalyst involves the expected reimbursement determination for WRAPSODY Cell-Impermeable Endoprosthesis. The company targeted September 1 for submission of its TPT application, with a decision anticipated by December 2025. Approval could take effect as early as January 2026, substantially accelerating the product’s commercial adoption and market penetration.

Should investors sell immediately? Or is it worth buying Merit Medical?

Any delays or setbacks in this regulatory process would significantly impact the commercial prospects for this key product. The reimbursement decision represents a pivotal moment for Merit Medical’s growth strategy in the coming year.

Diversified Portfolio Strengthens Market Position

Merit Medical’s strategic positioning across cardiovascular and endoscopy segments provides a solid foundation for continued market share expansion. The company maintains commitment to research and development, investing $24.4 million in the second quarter alone to drive innovation and product advancement.

As investors await both the third-quarter earnings report and the WRAPSODY reimbursement decision, the company’s diversified product portfolio and consistent R&D investment create multiple pathways for future growth. The upcoming quarterly results, particularly the consensus EPS estimate of approximately $0.82, will provide crucial insights into the company’s operational efficiency and continued growth trajectory amid current market conditions.